
    
      Primary study objectives include are to determine the pharmacodynamic (PD) profiles for
      treatment doses of dalteparin in pediatric subjects of different ages with cancer and venous
      thromboembolism (VTE), using anti-Xa (Xa) levels and a population PD analysis methodology,
      and to determine the median dose required to achieve therapeutic anti- Xa levels (0.5 to 1.0
      International Units [IU]/mL) based on subject age and weight.
    
  